^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pamvatamig (MCLA-129)

    i
    Company:
    Betta Pharma, Merus
    Drug class:
    EGFR inhibitor, c-MET inhibitor
    Related drugs:
    Apply
    Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation (NCT06015568)
    Phase 1
    Betta Pharmaceuticals Co., Ltd.
    Not yet recruiting
    Last update posted :
    08/29/2023
    Initiation :
    09/01/2023
    Primary completion :
    11/04/2028
    Completion :
    07/04/2029
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Semena (befotertinib) • pamvatamig (MCLA-129)
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors (NCT04930432)
    Phase 1/2
    Betta Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    12/21/2021
    Initiation :
    09/24/2021
    Primary completion :
    06/30/2024
    Completion :
    06/30/2025
    EGFR • IFNG • IL6 • TNFA • CXCL8 • IL2 • IL10 • IL1B
    |
    MET positive
    |
    pamvatamig (MCLA-129)